AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Orasure Technologies 2025 Q1 Earnings Losses Widen as Revenue Declines
Generated by AI AgentAinvest Earnings Report Digest
Thursday, May 8, 2025 7:17 am ET1min read
Orasure Technologies (OSUR) reported its fiscal 2025 Q1 earnings on May 7th, 2025. The company's financial performance missed expectations with a significant decline in revenue, dropping 46.1% from the previous year. The guidance for the next quarter aligns with market predictions, and while the company is navigating challenges, it is committed to innovation and operational efficiency. CEO Carrie Eglinton Manner expressed confidence in achieving future growth despite current uncertainties.
Revenue
Orasure Technologies' revenue in Q1 2025 fell to $29 million, a 46.1% decrease from $53.78 million in Q1 2024. The net product and services revenues totaled $29 million, with HIV diagnostics contributing $12.90 million and Sample Management Solutions generating $9.11 million. HCV diagnostics accounted for $4.33 million, while Risk Assessment Testing brought in $1.42 million. Other product and services revenues totaled $773,000, with COVID-19 revenues at $461,000. Non-product and services revenues were $934,000, bringing the net revenues to $29.93 million.
Earnings/Net Income
Orasure Technologies experienced a substantial increase in losses, with an EPS loss widening to $0.21 in Q1 2025 from $0.05 in Q1 2024. The net loss escalated to $16.04 million from a $3.58 million loss in the previous year, marking a 347.5% increase. The EPS reflects a negative financial outlook for the period.
Post-Earnings Price Action Review
The strategy of purchasing (OSUR) shares following a quarter-over-quarter revenue decline and holding them for 30 days has historically resulted in a 17.5% loss over the past five years. This performance is notably inferior compared to the market, which achieved a 21.4% return during the same timeframe. The prolonged holding period, coupled with the decline in OSUR's stock price, diminished any potential gains from the initial investment. This outcome underscores the critical importance of timing and prevailing market conditions when making investment decisions.
CEO Commentary
Guidance
Additional News
In recent developments, OraSure Technologies has authorized a $40 million stock repurchase program, reflecting its commitment to enhancing shareholder value. The company has also renewed its customer agreement with Myriad Genetics, emphasizing the continued importance of its FDA-cleared Oragene™ Dx saliva collection kits. Additionally, OraSure has divested certain assets related to its Risk Assessment Testing product line, with plans to complete its exit from this business in the second quarter. These strategic moves are part of OraSure's broader effort to streamline operations and focus on core business areas amid ongoing market challenges.
Revenue
Orasure Technologies' revenue in Q1 2025 fell to $29 million, a 46.1% decrease from $53.78 million in Q1 2024. The net product and services revenues totaled $29 million, with HIV diagnostics contributing $12.90 million and Sample Management Solutions generating $9.11 million. HCV diagnostics accounted for $4.33 million, while Risk Assessment Testing brought in $1.42 million. Other product and services revenues totaled $773,000, with COVID-19 revenues at $461,000. Non-product and services revenues were $934,000, bringing the net revenues to $29.93 million.
Earnings/Net Income
Orasure Technologies experienced a substantial increase in losses, with an EPS loss widening to $0.21 in Q1 2025 from $0.05 in Q1 2024. The net loss escalated to $16.04 million from a $3.58 million loss in the previous year, marking a 347.5% increase. The EPS reflects a negative financial outlook for the period.
Post-Earnings Price Action Review
The strategy of purchasing (OSUR) shares following a quarter-over-quarter revenue decline and holding them for 30 days has historically resulted in a 17.5% loss over the past five years. This performance is notably inferior compared to the market, which achieved a 21.4% return during the same timeframe. The prolonged holding period, coupled with the decline in OSUR's stock price, diminished any potential gains from the initial investment. This outcome underscores the critical importance of timing and prevailing market conditions when making investment decisions.
CEO Commentary
Guidance
Additional News
In recent developments, OraSure Technologies has authorized a $40 million stock repurchase program, reflecting its commitment to enhancing shareholder value. The company has also renewed its customer agreement with Myriad Genetics, emphasizing the continued importance of its FDA-cleared Oragene™ Dx saliva collection kits. Additionally, OraSure has divested certain assets related to its Risk Assessment Testing product line, with plans to complete its exit from this business in the second quarter. These strategic moves are part of OraSure's broader effort to streamline operations and focus on core business areas amid ongoing market challenges.
Ainvest Earnings Report Digest
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Electrovaya 2025 Q4 Earnings Record Net Income Surges 1896.5% from Loss
Dec.20 2025
Winnebago Industries 2026 Q1 Earnings Record Revenue and 205.8% Net Income Turnaround
Dec.19 2025
Paychex 2026 Q2 Earnings Beats Revenue Estimates, EPS Falls Short
Dec.19 2025
Lamb Weston Holdings 2026 Q2 Earnings 272% Net Income Surge and 1.1% Revenue Growth
Dec.19 2025
ConAgra Brands 2026 Q2 Earnings Sharp Net Loss Amid Revenue Decline and EPS Drop
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet